Category: Covid-19
-
Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratoryconfirmed with SARS-CoV-2 or with seasonal influenza – Version 2.0
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.
-
Protocol for a COVID-19 vaccine effectiveness study using health data registries
This protocol presents a common methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating EU/EEA Member States.
-
Communicable disease threats report, 23-29 January 2023, week 4
This issue of the Communicable Disease Threats Report (CDTR) covers the period 23-29 January 2023 and includes updates on COVID-19, diphtheriae, influenza, chikungunya, dengue and poliomyelitis.
-
Communicable disease threats report, 15-21 January 2023, week 3
This issue of the Communicable Disease Threats Report (CDTR) covers the period 15-21 January 2023 and includes updates on COVID-19, diphtheriae, influenza, Mpox and Cholera.
-
Communicable disease threats report, 9-13 January 2023, week 2
This issue of the CDTR covers the period 9-13 January 2023 and includes updates on COVID-19, Ebola, diphtheriae, influenza, measles and MERS-CoV.
-
ECDC assesses risk to the EU/EEA associated with Omicron XBB1.5 sub-lineage
In a Threat Assessment Brief released today, the European Centre for Disease Prevention and Control (ECDC) assesses the overall level of risk to the EU/EEA associated with the spread of the Omicron XBB.1.5 SARS-CoV-2 sub-lineage as low for the general population.
-
Threat Assessment Brief: Implications for the EU/EEA of the spread of the SARS-CoV-2 Omicron XBB.1.5 sub-lineage
According to the current ECDC assessment, there is moderate probability of XBB.1.5 becoming dominant in the EU/EEA and causing a substantial increase in the number of COVID-19 cases within the next one to two months.
-
E-learning: Case study: Crisis management and communication during a COVID-19 outbreak among foreign temporary workers
This case study is aimed at building capacity on outbreak response in municipalities that have large numbers of foreign temporary workers, where an outbreak response needs to involve the employers and possibly other municipal services, including public health services.
-
E-learning: COVID-19 infodemic management: risk communication and community engagement challenges, by WHO
This course covers key risk communication and community engagement (RCCE) principles and illustrates how they can be operationalized in the context of an extended outbreak that affects different populations with varying risk levels.
-
Pilot study outline for targeted genomic surveillance of SARS-CoV-2 in travellers in response to a worsening or unknown epidemiological situation in a third country
This document provides practical guidance to EU/EEA Member States willing to implement a pilot study for the harmonised and coordinated targeted genomic surveillance of SARS-CoV-2 at selected international points of entry (PoE), to complement national and international genomic surveillance.